Abstract
Traditional vaccine approaches have failed for HIV and novel strategies are now being sought to develop immunogens designed to elicit specific activity against known broad neutralization epitopes. Structure-based vaccine design has great potential but, so far, remains a largely unproven concept. Further structural information for the envelope (Env) glycoproteins, gp120 and gp41, would be extremely beneficial, particularly for understanding trimer-specific antibodies and their epitopes and to clarify the atomic details of the structural elements responsible for masking crucial epitopes and for mediating the conformational rearrangements undertaken during the process of receptor-binding and membrane fusion.
Keywords: HIV-1 vaccine, broadly neutralizing antibodies, immunogen, HIV-1 envelope, HIV-1 trimer, gp120, gp41, Vaccine, HIV, neutralization, glycoproteins, antibodies, B cell, T cell, anti-retroviral therapy, glycosylation, monoclonal antibodies, cryoelectron tomography, Gly-Ala-Gly, CD4-induced, influenza virus, ebola virus, visna virus, human respiratory syncytial virus, T-lymphotropic virus, leukemia, SIV mac239 trimers, HJ16, VRC01, CD4 binding site, Hyperglycosylation, High-Mannose Glycan Cluster, Z13e1
Current Pharmaceutical Design
Title: Structure-based Vaccine Design in HIV: Blind Men and the Elephant?
Volume: 16 Issue: 33
Author(s): Robert Pejchal and Ian A. Wilson
Affiliation:
Keywords: HIV-1 vaccine, broadly neutralizing antibodies, immunogen, HIV-1 envelope, HIV-1 trimer, gp120, gp41, Vaccine, HIV, neutralization, glycoproteins, antibodies, B cell, T cell, anti-retroviral therapy, glycosylation, monoclonal antibodies, cryoelectron tomography, Gly-Ala-Gly, CD4-induced, influenza virus, ebola virus, visna virus, human respiratory syncytial virus, T-lymphotropic virus, leukemia, SIV mac239 trimers, HJ16, VRC01, CD4 binding site, Hyperglycosylation, High-Mannose Glycan Cluster, Z13e1
Abstract: Traditional vaccine approaches have failed for HIV and novel strategies are now being sought to develop immunogens designed to elicit specific activity against known broad neutralization epitopes. Structure-based vaccine design has great potential but, so far, remains a largely unproven concept. Further structural information for the envelope (Env) glycoproteins, gp120 and gp41, would be extremely beneficial, particularly for understanding trimer-specific antibodies and their epitopes and to clarify the atomic details of the structural elements responsible for masking crucial epitopes and for mediating the conformational rearrangements undertaken during the process of receptor-binding and membrane fusion.
Export Options
About this article
Cite this article as:
Pejchal Robert and A. Wilson Ian, Structure-based Vaccine Design in HIV: Blind Men and the Elephant?, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079173
DOI https://dx.doi.org/10.2174/138161210794079173 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry The Effect of Stress Management Program on Perceived Stress in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Current Diabetes Reviews Pharmacotherapy of Aortic Stenosis-Success or Failure?
Current Pharmaceutical Biotechnology Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development
Current Drug Metabolism Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance
Current Medicinal Chemistry Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research Antidepressants and Sleep: Neurophysiology and Clinical Correlates
Current Psychiatry Reviews Impact of Quaternary Structure Dynamics on Allosteric Drug Discovery
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Drug Delivery & Formulation Chemokine-Chemokine Receptor Network in Immune Cell Trafficking
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Psychomotor Seizure Screening and in vitro Neuroprotection Assay of Hydrazones Derived from 2-Acetyl Thiophene
Central Nervous System Agents in Medicinal Chemistry Physiological Proteins in Therapeutics: A Current Review on Interferons
Mini-Reviews in Medicinal Chemistry Malformations of the Female Genital Tract and Embryological Bases
Current Women`s Health Reviews Age-Related Decline in Melatonin and Its MT1 Receptor Are Associated with Decreased Sensitivity to Melatonin and Enhanced Mammary Tumor Growth
Current Aging Science Expeditious Entry to Functionalized Pseudo-peptidic Organoselenide Redox Modulators via Sequential Ugi/SN Methodology
Anti-Cancer Agents in Medicinal Chemistry Effect of Nigella Sativa and Allium Sativum Coadminstered with Simvastatin in Dyslipidemia Patients: A Prospective, Randomized, Double-Blind Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: Protective or Damaging Immunity in Infection (Guest Editors: Jose Gutierrez and Antonio Sorlozano)]
Current Immunology Reviews (Discontinued) <i>Piper sarmentosum</i> Roxb. Attenuates Beta Amyloid (Aβ)-Induced Neurotoxicity <i>Via</i> the Inhibition of Amyloidogenesis and Tau Hyperphosphorylation in SH-SY5Y Cells
Current Alzheimer Research Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper
Current Alzheimer Research Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients
Current Pharmacogenomics and Personalized Medicine